Skip to content

Body Composition Analysis in Cirrhotic Undergoing Paracentesis

Body Composition Analysis in Cirrhotic Patients With Ascites Undergoing Paracentesis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02022150
Acronym
Paracentesis
Enrollment
20
Registered
2013-12-27
Start date
2012-12-31
Completion date
2021-12-31
Last updated
2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ascites, Liver Cirrhosis

Keywords

Paracentesis, Liver Cirrhosis, ascites, body composition

Brief summary

Ascites is a frequent complication of liver cirrhosis, initial treatment consists on diuretics intake, however, as the disease progresses this complication becomes more severe, consequently other therapeutic options are used. Paracentesis is indicated when severe ascites is present and it should be accompanied by albumin infusion. Nutritional status is generally affected in patients with liver cirrhosis, even more patients with severe ascites show decreased energy intake due to gastric compression.

Interventions

BEHAVIORALBody composition in paracentesis

Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation

Sponsors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Any genre. * Age 18-70 years old. * Diagnosis of liver cirrhosis of any etiology (documented by clinical, biochemical, radiological and / or biopsy. * Presence of high volume ascites * The signing of informed consent will be required for the inclusion of any patient.

Exclusion criteria

* Hepatic encephalopathy grade III or IV. 2) liver transplantation. * Congestive heart failure. * Hemodialysis. * Acute or chronic renal failure. * Nephrotic syndrome with protein loss. * Alcoholism active in the last 6 months. * Pregnancy. * upper gastrointestinal bleeding.

Design outcomes

Primary

MeasureTime frameDescription
Body compositionBaseline and 8 days post treatmentbioelectrical impedance vector analysis

Countries

Mexico

Contacts

Primary ContactAldo Torre, M.D. M.Sci
detoal@yahoo.com54870900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026